Apr 2024 Articles

Articles
The ’10 commandments’ for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
Schütt K, Federici M, Verket M, et al.
Journal:
Eur Heart J

First published: April 14, 2024 DOI: 10.1093/eurheartj/ehad881
View
- Share
Articles
Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography
Nurmohamed NS, van Rosendael AR, Danad I, et al.
Journal:
Eur Heart J

First published: April 12, 2024 DOI: 10.1093/eurheartj/ehae190
View
- Share
Articles
Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial
Nissen SE, Wolski K, Watts GF, et al.
Journal:
JAMA

First published: April 9, 2024 DOI: 10.1001/jama.2024.4504
View
- Share
Articles
An update on inclisiran for the treatment of elevated LDL cholesterol
Barkas F, Ray K
Journal:
Expert Opin Pharmacother

First published: April 8, 2024 DOI: 10.1080/14656566.2024.2337253
View
- Share
Articles
Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex
Cho L, Plutzky J, Brennan D, et al.
Journal:
Circulation

First published: April 6, 2024 DOI: 10.1161/CIRCULATIONAHA.123.067691
View
- Share
Articles
Cardiovascular benefit of evolocumab in 27,564 patients with and without autoimmune or inflammatory diseases: an analysis of the fourier trial
7. Zimerman A, Robert P. Ana KG, et al.
Journal:
JACC

First published: April 5, 2024 DOI: 10.1016/S0735-1097(24)03672-6
View
- Share
Articles
Unique features of dyslipidemia in women across a lifetime and a tailored approach to management
Patel N, Mittal N, Wilkinson MJ, et al.
Journal:
Am J Prev Cardiol

First published: April 5, 2024 DOI: 10.1016/j.ajpc.2024.100666
View
- Share
Articles
High lipoprotein(a): Actionable strategies for risk assessment and mitigation
Reyes-Soffer G, Yeang C, Michos ED, et al.
Journal:
Am J Prev Cardiol

First published: April 3, 2024 DOI: 10.1016/j.ajpc.2024.100651
View
- Share
Articles
Lipid-Lowering Therapy after Acute Coronary Syndrome
Pogran E, Burger AL, Zweiker D, et al.
Journal:
J Clin Med

First published: April 1, 2024 DOI: 10.3390/jcm13072043
View
- Share

1 2

Apr 2024 Articles

Articles

The ’10 commandments’ for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

Schütt K, Federici M, Verket M, et al.

Articles

Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography

Nurmohamed NS, van Rosendael AR, Danad I, et al.

Articles

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

Nissen SE, Wolski K, Watts GF, et al.

Articles

An update on inclisiran for the treatment of elevated LDL cholesterol

Barkas F, Ray K

Articles

Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex

Cho L, Plutzky J, Brennan D, et al.

Articles

Cardiovascular benefit of evolocumab in 27,564 patients with and without autoimmune or inflammatory diseases: an analysis of the fourier trial

7. Zimerman A, Robert P. Ana KG, et al.

Articles

Unique features of dyslipidemia in women across a lifetime and a tailored approach to management

Patel N, Mittal N, Wilkinson MJ, et al.

Articles

High lipoprotein(a): Actionable strategies for risk assessment and mitigation

Reyes-Soffer G, Yeang C, Michos ED, et al.

Articles

Lipid-Lowering Therapy after Acute Coronary Syndrome

Pogran E, Burger AL, Zweiker D, et al.

Articles

The ’10 commandments’ for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

Schütt K, Federici M, Verket M, et al.

Share

Articles

Atherosclerosis evaluation and cardiovascular risk estimation using coronary computed tomography angiography

Nurmohamed NS, van Rosendael AR, Danad I, et al.

Share

Articles

Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial

Nissen SE, Wolski K, Watts GF, et al.

Share

Articles

An update on inclisiran for the treatment of elevated LDL cholesterol

Barkas F, Ray K

Share

Articles

Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex

Cho L, Plutzky J, Brennan D, et al.

Share

Articles

Cardiovascular benefit of evolocumab in 27,564 patients with and without autoimmune or inflammatory diseases: an analysis of the fourier trial

7. Zimerman A, Robert P. Ana KG, et al.

Share

Articles

Unique features of dyslipidemia in women across a lifetime and a tailored approach to management

Patel N, Mittal N, Wilkinson MJ, et al.

Share

Articles

High lipoprotein(a): Actionable strategies for risk assessment and mitigation

Reyes-Soffer G, Yeang C, Michos ED, et al.

Share

Articles

Lipid-Lowering Therapy after Acute Coronary Syndrome

Pogran E, Burger AL, Zweiker D, et al.

Share